Wall Street Zen Downgrades Charles River Laboratories International (NYSE:CRL) to Hold

Charles River Laboratories International (NYSE:CRL) was downgraded by research analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a note issued to investors on Saturday.

A number of other equities research analysts have also weighed in on CRL. JPMorgan Chase & Co. lifted their price objective on Charles River Laboratories International from $165.00 to $190.00 and gave the stock a “neutral” rating in a research report on Monday, December 15th. TD Cowen dropped their price target on Charles River Laboratories International from $251.00 to $235.00 and set a “buy” rating for the company in a research note on Friday. Argus set a $200.00 price objective on shares of Charles River Laboratories International in a research report on Monday, November 17th. Mizuho decreased their price objective on shares of Charles River Laboratories International from $215.00 to $175.00 and set a “neutral” rating for the company in a report on Friday. Finally, Barclays cut their target price on shares of Charles River Laboratories International from $215.00 to $200.00 and set an “overweight” rating on the stock in a research note on Thursday. Ten investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Charles River Laboratories International presently has an average rating of “Moderate Buy” and an average price target of $205.77.

Charles River Laboratories International Price Performance

Shares of Charles River Laboratories International stock opened at $169.26 on Friday. The company’s fifty day simple moving average is $200.37 and its two-hundred day simple moving average is $179.34. Charles River Laboratories International has a 12-month low of $91.86 and a 12-month high of $228.88. The firm has a market cap of $8.33 billion, a PE ratio of -57.18, a price-to-earnings-growth ratio of 4.86 and a beta of 1.63. The company has a quick ratio of 1.10, a current ratio of 1.29 and a debt-to-equity ratio of 0.67.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings data on Wednesday, February 18th. The medical research company reported $2.39 EPS for the quarter, beating the consensus estimate of $2.33 by $0.06. The firm had revenue of $994.23 million during the quarter, compared to the consensus estimate of $986.98 million. Charles River Laboratories International had a negative net margin of 3.59% and a positive return on equity of 15.60%. The company’s quarterly revenue was down .8% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.66 earnings per share. Charles River Laboratories International has set its FY 2026 guidance at 10.700-11.200 EPS. As a group, equities analysts expect that Charles River Laboratories International will post 9.36 EPS for the current year.

Hedge Funds Weigh In On Charles River Laboratories International

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. boosted its position in shares of Charles River Laboratories International by 0.8% in the 4th quarter. Vanguard Group Inc. now owns 5,887,175 shares of the medical research company’s stock worth $1,174,374,000 after purchasing an additional 47,432 shares in the last quarter. Invesco Ltd. raised its stake in Charles River Laboratories International by 115.8% during the fourth quarter. Invesco Ltd. now owns 2,696,150 shares of the medical research company’s stock valued at $537,828,000 after buying an additional 1,446,972 shares during the last quarter. State Street Corp boosted its holdings in Charles River Laboratories International by 2.2% in the fourth quarter. State Street Corp now owns 1,871,688 shares of the medical research company’s stock worth $373,364,000 after acquiring an additional 40,535 shares in the last quarter. Dimensional Fund Advisors LP grew its stake in shares of Charles River Laboratories International by 27.5% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,442,224 shares of the medical research company’s stock worth $287,703,000 after acquiring an additional 311,319 shares during the last quarter. Finally, Ariel Investments LLC increased its holdings in shares of Charles River Laboratories International by 28.6% during the second quarter. Ariel Investments LLC now owns 1,415,348 shares of the medical research company’s stock valued at $214,751,000 after acquiring an additional 314,572 shares in the last quarter. Institutional investors own 98.91% of the company’s stock.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.